Menopur (Menotrophin)

Menotropin contains both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). After injection, FSH stimulates granulosa cells to grow and produce estrogen, while LH activates theca cells and mature follicles, promoting androgen conversion and final oocyte maturation, thereby facilitating ovulation.

The dose of Menopur is individualized. A qualified fertility specialist determines the amount and frequency based on the patient’s ovarian reserve, response to previous cycles, and the specific assisted‑reproduction protocol.

Menopur is intended for use before conception to induce ovulation. Its safety in an established pregnancy or during breastfeeding has not been established, and it should only be used under the guidance of a reproductive specialist.

To order Menopur, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and required import documentation.

The primary alternative to Menopur is recombinant FSH/LH preparations. Menopur is a purified urinary‑derived gonadotropin containing both FSH and LH activity in a fixed ratio, whereas recombinant products are individually manufactured and can be dosed separately. Clinical outcomes are comparable, but choice often depends on physician preference, cost and patient response.

Menopur must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product reaches room temperature for a short period, it may still be used, but it should be returned to refrigeration promptly.

Menopur is administered by a healthcare professional as an intramuscular or subcutaneous injection. The injection site is typically the abdomen or thigh, and the exact technique, volume and timing are determined by the treating physician as part of the ovarian stimulation protocol.

The most serious risks associated with Menopur include ovarian hyperstimulation syndrome (OHSS), which can cause severe ovarian enlargement and fluid shifts, thromboembolic events such as blood clots, and rare allergic reactions that may progress to anaphylaxis. Prompt medical attention is required if any of these occur.

Menopur is contraindicated in women with active ovarian cysts, uncontrolled thyroid disease, estrogen‑dependent tumors, severe ovarian hyperstimulation syndrome, or known hypersensitivity to menotropin or any excipients. It should also be avoided in patients who are already pregnant.